PSI-697

Cat. No.: HY-15526
CAS No.: 851546-61-7
Molecular Formula: C₂₁H₁₈ClNO₃
Molecular Weight: 367.83
Target: Others
Pathway: Others
Storage: Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 45.8 mg/mL (124.51 mM)
* “≥” means soluble, but saturation unknown.

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Mass</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 mM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.7186 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 mM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.5437 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 mM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.2719 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description
PSI-697 is an oral P-selectin inhibitor with an IC₅₀ of 125 μM[1].

IC₅₀ & Target
IC₅₀: 125 μM (P-selectin)[1]

In Vitro
PSI-697 inhibits the binding of a soluble human P-selectin to PSGL-1, in a reproducible concentration-dependent manner inhibiting 50% of binding at a concentration of 125 μM in vitro[1].

In Vivo
PSI-697 (0-50 mg/kg; p.o.) significantly reduces the number of rolling leukocytes by 39% versus vehicle control[1].
PSI-697 (100 mg/kg; p.o.) reduces thrombus weight by 18% relative to vehicle, without prolonging bleeding time in a rat venous thrombosis model[1].
PSI-697 (30 mg/kg; p.o.; daily; 6 days) promotes thrombus resolution and decreases inflammation in a baboon model of venous thrombosis[2].
PSI-697 (30 mg/kg; i.g.; daily) decreases vein wall injury in a rat stenosis model of venous thrombosis[2].
Animal Model: 4-5 weeks male Sprague-Dawley rat (50-100 g)[1]

Dosage: 0 mg/kg, 30 mg/kg, 50 mg/kg

Administration: Oral administration

Result: At an oral dose of 50 mg/kg reduced the number of rolling leukocytes by 39% versus vehicle control.

REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898       Fax: 609-228-5909       E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA